Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00082121 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery

A Phase 2 study of Myocardial Ischemia and Aortic Valve Insufficiency, sponsored by Avant Immunotherapeutics.

Completed
Registry status
Phase 2
Development phase
300
Enrollment target
18
Study locations

NCT00082121 is a Phase 2 study of Myocardial Ischemia and Aortic Valve Insufficiency that has completed, run by Avant Immunotherapeutics. The registered enrollment target is 300 participants, below the 2,128-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (86% lower). The trial reports 18 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00082121, a Phase 2 study of Myocardial Ischemia and Aortic Valve Insufficiency, has completed, sponsored by Avant Immunotherapeutics.

COMPLETED
Registry status
Phase 2
Development phase
300 participants
Enrollment target
18
Study locations

Study Summary

The purpose of this study is to determine if the study drug (TP10), which blocks complement release, can reduce such side effects of complement inflammation as chest pain or heart attacks and be taken safely in women who undergo cardiopulmonary bypass surgery.

Conditions Studied

Myocardial Ischemia Aortic Valve Insufficiency Mitral Valve Insufficiency Coronary Arteriosclerosis

Interventions

  • DRUG TP10

Study Locations (18)

Florida

  • - Gainesville
  • - Orlando
  • - Sarasota

Massachusetts

  • - Boston
  • - Springfield

Michigan

  • - Detroit
  • - Lansing

Wisconsin

  • - Madison
  • - Milwaukee

California

  • - San Francisco

District of Columbia

  • - Washington D.C.

Georgia

  • - Atlanta

Illinois

  • - Chicago

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2004-04
Est. Completion 2005-12
Phase Phase 2

Sponsor

Avant Immunotherapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00082121

The ClinicalTrials.gov registry entry for NCT00082121 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,128-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (86% lower). The listed sponsor is Avant Immunotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Myocardial Ischemia appearing as the primary indexed condition, and to 1 intervention - of which TP10 is the first listed.

NCT00082121 reports 18 study locations spanning 13 distinct geographic areas - top geographies include Florida, Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT00082121 about?

NCT00082121 is a clinical study titled "Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery". The purpose of this study is to determine if the study drug (TP10), which blocks complement release, can reduce such side effects of complement inflammation as chest pain or heart attacks and be taken safely in women who undergo cardiopulmonary bypass surgery.

What is the current status of trial NCT00082121?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2004-04. Estimated completion is 2005-12.

What conditions does trial NCT00082121 study?

This clinical trial studies the following conditions: Myocardial Ischemia, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Coronary Arteriosclerosis.

What interventions are being tested in trial NCT00082121?

The interventions under investigation include: TP10 (DRUG).

Who is sponsoring clinical trial NCT00082121?

This trial is sponsored by Avant Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00082121 being conducted?

This trial has 18 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myocardial Ischemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myocardial Ischemia

All registered trials for this condition

Aortic Valve Insufficiency

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.